Study | Exclusion reasons | Remarks | Reference(s) | ||
---|---|---|---|---|---|
MDX-1106 excluded (no control group), 2015 | randomized controlled trial |
George JAMA Oncol 2016; 2:1179-86 10.1001/jamaoncol.2016.0775 Motzer J. Clin. Oncol. 2015; 33:1430-7 10.1200/JCO.2014.59.0703 |
|||
KEYNOTE-B61, 2023 | randomized controlled trial | inadequate or absent control group |
Albiges L Lancet Oncology july 2023 10.1016/S1470-2045(23)00276-0 |
||
NCT05172440, 0 | randomized controlled trial | inadequate or absent control group | single arm study | ||
PRISM, 2019 | randomized controlled trial | inadequate or absent control group | phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile. |
Buckley BMC Cancer 2019; 19:1102 10.1186/s12885-019-6273-1 Naveen S. Vasudev JCO 42, 312-323(2024) 10.1200/JCO.23.00236 |
|
COSMIC-313, 2023 | randomized controlled trial | not relevant exposure |
Choueiri TK N Engl J Med 2023;388:1767-1778 May 2023 10.1056/NEJMoa2212851 Choueiri TK N Engl J Med 2023; 388:1767-1778-. 10.1056/NEJMoa2212851 |